A SINGLE ARM, OPEN LABEL MULTICENTRE EXTENSION STUDY TO EVALUATE THE EFFECTIVENESS AND SAFETY OF OCRELIZUMAB INPATIENTS WITH MULTIPLE SCLEROSIS PREVIOUSLY ENROLLED IN A F. HOFFMANN-LA ROCHE SPONSORED OCRELIZUMAB PHASE IIIb/IV CLINICAL TRIA

F. Hoffmann-La Roche Ltd0 个研究点目标入组 1,127 人开始时间: 2021年6月1日最近更新: 2021年8月2日

适应症

试验速览

暂无简介。

•- Able to comply with the study protocol, in the investigator’s judgment
•- Completed the treatment period of Roche sponsored ocrelizumab Parent-trial (including the female patients who were pregnant during the parent studies and are still in the safety follow up period) and who in the opinion of the investigator may benefit from treatment with ocrelizumab and so are eligible for ocrelizumab re-treatment
•- Meet re-treatment criteria with ocrelizumab
•- Patients who became pregnant by chance between the last visit of the parent study and screening of this study, as confirmed by pregnancy tests at screening, will enter the safety follow-up immediately and re-start the treatment after birth and breastfeeding are over, as per re-treatment criteria
•- For women of childbearing potential: agreement to remain abstinent or use an acceptable birth control method during the treatment period and for at least 6 months or longer after the final dose of ocrelizumab, as applicable in the local ocrelizumab package leaflet.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 1127
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•- Hypersensitivity to ocrelizumab or to any of its excipients
•- Patients in a severely immunocompromised state until the condition resolves
•- Evidence of any adverse event potentially attributable to ocrelizumab, for which the local label recommends permanent discontinuation
•- Existence of a contra-indication as per ocrelizumab package leaflet
•- Prohibited concomitant medication use
•- Patients intending to become pregnant during the study or within 6 months after the last dose of the study drug in the parent study
•- Patients who discontinued ocrelizumab, exemption made for treatment discontinuation due to unplanned pregnancy and breastfeeding for patients who continued clinical study assessments in the safety follow-up of the parent study

发起方